Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07318389 · ClinicalTrials.gov registry record · Early Phase 1
ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer
A Early Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Not yet
- Registry status
- Early Phase 1
- Development phase
- 100
- Enrollment target
NCT07318389: Clinical Trial Early Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT07318389 is a Early Phase 1 study that has not yet begun recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 100 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07318389, a Early Phase 1 study, has not yet begun recruiting, sponsored by M.D. Anderson Cancer Center.
- NOT YET RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 100 participants
- Enrollment target
Study Summary
To find out if certain drug/therapy combinations that are targeted to individual patients based on characteristics of their disease types may help to control the disease.
Interventions
- DRUG Bevacizumab
- DRUG Cetuximab
- OTHER SOC (Standard of care)
- DRUG FOLFIRI
- DRUG Panitumumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2026-06-10 |
| Est. Completion | 2029-11-14 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07318389
The ClinicalTrials.gov registry entry for NCT07318389 describes a study currently listed as not yet recruiting, categorized as Early Phase 1. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Bevacizumab is the first listed.
NCT07318389 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07318389 about?
NCT07318389 is a clinical study titled "ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer". To find out if certain drug/therapy combinations that are targeted to individual patients based on characteristics of their disease types may help to control the disease.
What is the current status of trial NCT07318389?
This trial is currently not yet recruiting. It is a Early Phase 1 study. The enrollment target is 100 participants. The study started on 2026-06-10. Estimated completion is 2029-11-14.
What interventions are being tested in trial NCT07318389?
The interventions under investigation include: Bevacizumab (DRUG), Cetuximab (DRUG), SOC (Standard of care) (OTHER), FOLFIRI (DRUG), Panitumumab (DRUG).
Who is sponsoring clinical trial NCT07318389?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.